Kumquat Biosciences vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Kumquat Biosciences is an oncology-focused drug discovery company developing novel cancer therapeutics through internal research programs and academic collaborations; early-stage biotech with undisclosed funding; based in San Francisco.
About
Kumquat Biosciences is a San Francisco-based biotechnology company focused on oncology drug discovery and development. The company applies internal scientific expertise and collaborations with leading academic research institutions to identify and advance novel cancer therapeutic candidates. Kumquat operates in the early-to-mid stage of drug development, working on programs aimed at targeting cancer biology through mechanisms that may be underexplored in the current pharmaceutical industry pipeline.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.